Wädenswil/Zurich, Switzerland, 10 December 2019 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020. After seven years in the position, Matyas Vegh has decided to pursue new opportunities outside the company.
“I am grateful to Matyas for his outstanding contributions to the success of Creoptix. Thanks to his achievements, the company is now a well-funded technology leader on a path of accelerated growth. The entire Creoptix team wishes Matyas all the best for his future endeavors,” said Kaspar Cottier, Founder and Chief Technology Officer of Creoptix. “Line joins us at the ideal time as she has an outstanding track record of turning great lab equipment into outstanding commercial successes. We look forward very much to her joining us in January and to benefiting from her experience and leadership qualities as we continue to build Creoptix’ success story.”
Line Stigen Raquet joins Creoptix from Mettler Toledo, where she has most recently served as Vice President of Business Development Life Sciences. Before that she was Head of Strategic Business Unit pH Lab, with full P&L responsibility, significantly accelerating revenue growth over a three-year period across the portfolio of instruments, consumables, software and service. Line was responsible for the entire value chain, from product ideation and development, industrialization, service and end-customer support, marketing and life-cycle management. Prior to Mettler Toledo, Line spent almost a decade at QIAGEN, where she successfully built and led the first APAC regional marketing team in Asia. During her career, she worked in the US, China and the UK before moving to Switzerland.
Line Stigen Raquet commented: “I am incredibly excited to be joining Creoptix at this key stage in its growth. The Creoptix WAVE is a powerful, cutting-edge product portfolio with the potential to bring a paradigm shift in kinetic analysis and molecular characterization and deliver huge benefits to our customers in areas including drug discovery and academia. The team is exceptionally talented and has done a phenomenal job in bringing the portfolio to market. I look forward to driving the next phase of commercial acceleration and unlocking our full potential in this space.”
“Creoptix is expanding its market presence with its next-generation WAVEsystems and seeking to strengthen its commercial operations in Europe and the US. Line is therefore a perfect fit for the business, and we are delighted to welcome her to the team at Creoptix,” added Robert Schier, Vice-Chairman of Creoptix and Investment Director PE/VC Health-Tech at Swisscanto Invest.
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics and other molecules even in biofluids like undiluted serum or plasma. www.creoptix.com
+41 79 256 77 73